Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I trial of intravenous BI 4060107 in advanced or metastatic solid tumors
jRCT2031260555Phase 1Recruiting
- Sponsor
- Aimed Bio
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of ODS025 in Nonhematologic neoplasms, sponsored by Aimed Bio. Primary endpoint: Occurrence of dose-limiting toxicities. Started Oct 2026; status: recruiting.
02
Drugs
ODS025
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031260555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260555.